As reported on BioSpace, AstraZeneca has entered a major artificial intelligence-focused research collaboration with biotechnology company insitro, committing up to $1.5 billion in potential payments to identify new drug targets for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.
Under the agreement, insitro will apply its Virtual Human AI platform to analyze disease biology and uncover potential therapeutic targets. AstraZeneca will be responsible for advancing any resulting candidates through the drug development process. The deal includes an upfront payment of $40 million, with additional milestone payments and royalties that could bring the total value of the partnership to approximately $1.5 billion.
The collaboration strengthens AstraZeneca’s presence in the increasingly competitive MASH market. The company already has the anti-fibrotic candidate AZD2389 in early-stage clinical development. Interest in the field has surged in recent years following the approval of Madrigal Pharmaceuticals’ Rezdiffra, the first FDA-approved treatment for MASH, which helped renew investment across the sector. Major pharmaceutical companies including Novo Nordisk, Roche, and GSK have since expanded their involvement through acquisitions, licensing agreements, and internal programs.
AstraZeneca’s renewed focus on liver disease comes after a setback in late 2025, when it discontinued AZD2693, a MASH treatment developed in partnership with Ionis Pharmaceuticals, following disappointing Phase 2 trial results.
In cardiovascular disease, AstraZeneca maintains a broader pipeline but has also faced recent challenges. The company’s partnered drug Wainua, which received approval for hereditary transthyretin-mediated amyloidosis with polyneuropathy in 2023, recently failed a Phase 3 study evaluating its use in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The outcome was viewed as a significant disappointment for both AstraZeneca and the broader amyloidosis field.
Despite that setback, the company continues to advance additional cardiology assets, including AZD4063, an investigational therapy currently in Phase 1 testing for R14del dilated cardiomyopathy.
For insitro, the agreement represents another high-profile partnership aimed at validating its AI-powered drug discovery platform. The company has previously established collaborations with several large pharmaceutical organizations, including Bristol Myers Squibb and Eli Lilly, as part of its strategy to build a pipeline of AI-derived therapies. However, insitro has also faced financial pressures, including a workforce reduction in 2025 intended to extend operational funding amid challenging market conditions.
The new alliance highlights the pharmaceutical industry’s growing reliance on artificial intelligence to improve target selection, an area widely viewed as one of the most critical determinants of success in drug research and development. By combining AI-driven biological insights with AstraZeneca’s development capabilities, the companies hope to identify novel treatments for two disease areas that continue to present substantial unmet medical needs.
